( or in combination were administered at...)Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies,Health

or in combination were administered at different time points. Treatment with the combination regimen reduced the growth of small tumors by 80% to 82% and of well-established tumors by 92% to 94%. The anti-tumor effect of the combination regimen was significantly superior to that of the individual treatments (P < 0.01). Yet the combination therapy was no more toxic to the mice than was docetaxel alone as judged by physical signs and body weight changes.

Tumor microvessel density, which is correlated with tumor growth rates, was further reduced in tumors treated with the combination regimen compared with tumors from single agent-treated animals. In addition, serum PSA levels in combination-treated mice registered a significantly greater decrease (P < 0.05) in one of the tumor models compared to the decrease seen in either the docetaxel-treated or 2aG4-treated animals.

Bavituximab is a targeted monoclonal antibody that binds to a phospholipid called phosphatidylserine, which is located on the inside of normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, thus creating a specific target for anti-cancer treatments. Once bound to the tumor blood vessels, bavituximab alerts the body's immune system to attack the tumor's blood supply, stopping the flow of oxygen and nutrients to the tumor cells and resulting in tumor cell death. As an anti-cancer immunotherapeutic, bavituximab may have broad potential in a wide variety of solid cancers. It is currently in Phase Ia cancer safety trials as a monotherapy and in a Phase Ib trial in combination with docetaxel and other chemotherapy agents in patients with advanced solid cancers, including prostate, breast and lung cancer. Interim data indicate that more than half of the cancer patients in this study who have completed treatment to date were assessed as demonstrating stable disease or an objective response.

Prostate cancer is the most commonly diagnosed c
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes